Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: ACS Chem Neurosci. 2020 Jun 19;11(13):1937–1943. doi: 10.1021/acschemneuro.0c00093

Table 2.

Neurological diseases predicted to be decreased in response to treatment (based on IPA; 2.5-fold cutoff, p < 0.05).

Diseases or functions annotation p-Value Activation z-score No. of molecules Selected genes
Movement disorders 1.93E-011 −3.773 149 OPRM1, PAX6, ATXN2
Seizure disorders 6.38E-05 −3.588 63 SYN2, OPRM1, ATXN2
Paraparesis 0.000152 −2.236 5 CTSF, NDRG1, PLP1
Ataxia 0.00015 −2.775 35 PAX6, SOD2, PLP1
Congenital malformation of brain 0.00013 −3.43 36 PAX6, CREBBP, AKT3